title: Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control.
abstract: We evaluated the effect of improving glycaemic control with intensive insulin therapy on LDL susceptibility to oxidation, electronegative LDL proportion, and LDL subfraction phenotype in a group of 25 patients with short-duration insulin-dependent diabetes mellitus (IDDM); 25 matched healthy control subjects were also studied. LDL susceptibility to oxidation was measured by continuous monitoring of conjugated diene formation. Electronegative LDL was isolated by anion exchange chromatography, and quantified as percentage of total LDL. Six LDL subfractions were isolated by density gradient ultracentrifugation and phenotype A or B classified as the quotient (LDL1-LDL3)/(LDL4-LDL6). Compared to the control group, IDDM subjects with poor glycaemic control showed higher electronegative LDL (19.03 +/- 10.09 vs 9.59 +/- 2.98%, p < 0.001), similar LDL subfraction phenotype and lower susceptibility to oxidation (lag phase 45.6 +/- 8.8 vs 41.2 +/- 4.7 min, p < 0.05). After three months of intensive insulin therapy, HbA1c decreased from 10.88 +/- 2.43 to 5.69 +/- 1.54% (p < 0.001), and electronegative LDL to 13.84 +/- 5.15% (p < 0.05). No changes in LDL susceptibility to oxidation or LDL subfraction phenotype were observed. Electronegative LDL appeared significantly correlated to HbA1c and fructosamine (p < 0.01 and p < 0.001) only in poorly controlled IDDM patients. These findings suggest that high electronegative LDL in IDDM subjects is related to the degree of glycaemic control, and could therefore be due to LDL glycation rather than to LDL oxidation or changes in LDL subfraction phenotype.
authors.affiliation: Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Sánchez-Quesada
authors.forename: A
authors.initials: A
authors.lastname: Pérez
authors.forename: A
authors.initials: A
authors.lastname: Caixàs
authors.forename: J
authors.initials: J
authors.lastname: Ordónmez-Llanos
authors.forename: G
authors.initials: G
authors.lastname: Carreras
authors.forename: A
authors.initials: A
authors.lastname: Payés
authors.forename: F
authors.initials: F
authors.lastname: González-Sastre
authors.forename: A
authors.initials: A
authors.lastname: de Leiva
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D002850:Chromatography, Gel; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007328:Insulin / Q000494:pharmacology* / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry* / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D012016:Reference Values
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008077:Lipoproteins, LDL